NO325232B1 - Transdermalt plaster for administrering av estradiol og et annet steroid - Google Patents
Transdermalt plaster for administrering av estradiol og et annet steroid Download PDFInfo
- Publication number
- NO325232B1 NO325232B1 NO19990179A NO990179A NO325232B1 NO 325232 B1 NO325232 B1 NO 325232B1 NO 19990179 A NO19990179 A NO 19990179A NO 990179 A NO990179 A NO 990179A NO 325232 B1 NO325232 B1 NO 325232B1
- Authority
- NO
- Norway
- Prior art keywords
- steroid
- estradiol
- concentration
- matrix
- flux
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title claims abstract description 52
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 title claims abstract description 31
- 229960005309 estradiol Drugs 0.000 title claims abstract description 31
- 229930182833 estradiol Natural products 0.000 title claims abstract description 31
- 230000004907 flux Effects 0.000 claims abstract description 81
- 239000011159 matrix material Substances 0.000 claims abstract description 66
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims abstract description 8
- 239000003961 penetration enhancing agent Substances 0.000 claims abstract description 3
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 68
- 229960003604 testosterone Drugs 0.000 claims description 34
- 229920001577 copolymer Polymers 0.000 claims description 17
- GOXQRTZXKQZDDN-UHFFFAOYSA-N 2-Ethylhexyl acrylate Chemical compound CCCCC(CC)COC(=O)C=C GOXQRTZXKQZDDN-UHFFFAOYSA-N 0.000 claims description 11
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 9
- 239000001593 sorbitan monooleate Substances 0.000 claims description 9
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 9
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 9
- IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 8
- 229960001652 norethindrone acetate Drugs 0.000 claims description 8
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 6
- 229960004400 levonorgestrel Drugs 0.000 claims description 6
- 229940053934 norethindrone Drugs 0.000 claims description 6
- VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 6
- GCKMFJBGXUYNAG-UHFFFAOYSA-N 17alpha-methyltestosterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C)(O)C1(C)CC2 GCKMFJBGXUYNAG-UHFFFAOYSA-N 0.000 claims description 3
- GCKMFJBGXUYNAG-HLXURNFRSA-N Methyltestosterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)CC2 GCKMFJBGXUYNAG-HLXURNFRSA-N 0.000 claims description 3
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 3
- 229960005471 androstenedione Drugs 0.000 claims description 3
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 3
- 229960004976 desogestrel Drugs 0.000 claims description 3
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 3
- SIGSPDASOTUPFS-XUDSTZEESA-N gestodene Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](C=C4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 SIGSPDASOTUPFS-XUDSTZEESA-N 0.000 claims description 3
- 229960005352 gestodene Drugs 0.000 claims description 3
- 229960001566 methyltestosterone Drugs 0.000 claims description 3
- 229960003387 progesterone Drugs 0.000 claims description 3
- 239000000186 progesterone Substances 0.000 claims description 3
- 229920006243 acrylic copolymer Polymers 0.000 abstract description 19
- 239000000203 mixture Substances 0.000 description 85
- 238000009472 formulation Methods 0.000 description 74
- 210000003491 skin Anatomy 0.000 description 45
- 238000000338 in vitro Methods 0.000 description 34
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 30
- 229940079593 drug Drugs 0.000 description 28
- 239000003814 drug Substances 0.000 description 28
- 230000001070 adhesive effect Effects 0.000 description 22
- 239000000853 adhesive Substances 0.000 description 21
- 239000003292 glue Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 11
- 238000007792 addition Methods 0.000 description 10
- 238000005266 casting Methods 0.000 description 10
- 229960004592 isopropanol Drugs 0.000 description 10
- 238000012417 linear regression Methods 0.000 description 8
- 241000769223 Thenea Species 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 4
- 239000003623 enhancer Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- ARIWANIATODDMH-AWEZNQCLSA-N 1-lauroyl-sn-glycerol Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)CO ARIWANIATODDMH-AWEZNQCLSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FDVCQFAKOKLXGE-UHFFFAOYSA-N 216978-79-9 Chemical compound C1CC(C)(C)C2=CC(C=O)=CC3=C2N1CCC3(C)C FDVCQFAKOKLXGE-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WDPFQABQVGJEBZ-MAKOZQESSA-N Bothermon Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 WDPFQABQVGJEBZ-MAKOZQESSA-N 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N Lauric acid monoglyceride Natural products CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002159 estradiols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229940116335 lauramide Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/683,892 US5783208A (en) | 1996-07-19 | 1996-07-19 | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
| PCT/US1997/011673 WO1998003137A1 (en) | 1996-07-19 | 1997-07-02 | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO990179L NO990179L (no) | 1999-01-15 |
| NO990179D0 NO990179D0 (no) | 1999-01-15 |
| NO325232B1 true NO325232B1 (no) | 2008-03-03 |
Family
ID=24745888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19990179A NO325232B1 (no) | 1996-07-19 | 1999-01-15 | Transdermalt plaster for administrering av estradiol og et annet steroid |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US5783208A (de) |
| EP (1) | EP0921774B1 (de) |
| JP (2) | JP4212115B2 (de) |
| KR (1) | KR100628796B1 (de) |
| CN (2) | CN100536835C (de) |
| AT (1) | ATE339172T1 (de) |
| AU (1) | AU714590B2 (de) |
| BR (1) | BR9710738A (de) |
| CA (1) | CA2259532C (de) |
| DE (1) | DE69736671T2 (de) |
| DK (1) | DK0921774T3 (de) |
| ES (1) | ES2271970T3 (de) |
| HK (2) | HK1020864A1 (de) |
| HU (1) | HUP9904369A3 (de) |
| IL (1) | IL127708A (de) |
| NO (1) | NO325232B1 (de) |
| NZ (1) | NZ333558A (de) |
| PL (1) | PL188009B1 (de) |
| PT (1) | PT921774E (de) |
| WO (1) | WO1998003137A1 (de) |
| ZA (1) | ZA976035B (de) |
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5252334A (en) * | 1989-09-08 | 1993-10-12 | Cygnus Therapeutic Systems | Solid matrix system for transdermal drug delivery |
| US6407082B1 (en) * | 1996-09-13 | 2002-06-18 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a vitamin D compound |
| US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
| UA48973C2 (uk) * | 1995-06-07 | 2002-09-16 | Орто-Макнейл Фармасьютікалз Інк. | Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції |
| US6511970B1 (en) | 1996-09-13 | 2003-01-28 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium |
| US6034074A (en) | 1996-09-13 | 2000-03-07 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of a Vitamin D compound |
| US6765002B2 (en) | 2000-03-21 | 2004-07-20 | Gustavo Rodriguez | Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium |
| US6028064A (en) | 1996-09-13 | 2000-02-22 | New Life Pharmaceuticals Inc. | Prevention of ovarian cancer by administration of progestin products |
| US7153845B2 (en) * | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6248358B1 (en) | 1998-08-25 | 2001-06-19 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets and methods of making and using the same |
| US6624200B2 (en) | 1998-08-25 | 2003-09-23 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US8765177B2 (en) * | 1997-09-12 | 2014-07-01 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| DE19834007C1 (de) * | 1998-07-29 | 2000-02-24 | Lohmann Therapie Syst Lts | Estradiolhaltiges Pflaster zur transdermalen Applikation von Hormonen und seine Verwendung |
| CN1192766C (zh) * | 1998-10-23 | 2005-03-16 | 伊迪亚股份公司 | 开发、测试和使用用于改进的有效负载和可控制性解缔/缔合速度的大分子和复合聚集体的缔合物的方法 |
| US6984404B1 (en) | 1998-11-18 | 2006-01-10 | University Of Florida Research Foundation, Inc. | Methods for preparing coated drug particles and pharmaceutical formulations thereof |
| AU2051600A (en) * | 1998-12-10 | 2000-06-26 | Board Of Regents, The University Of Texas System | Compositions and methods of modulating cholesterol metabolism |
| DK1031347T3 (da) | 1999-01-27 | 2002-07-08 | Idea Ag | Transnasal transport/immunisering med meget tilpasselige bærere |
| ES2173678T3 (es) | 1999-01-27 | 2002-10-16 | Idea Ag | Vacunacion no invasiva a traves de la piel. |
| US6297337B1 (en) | 1999-05-19 | 2001-10-02 | Pmd Holdings Corp. | Bioadhesive polymer compositions |
| EP1754488A1 (de) | 1999-05-24 | 2007-02-21 | Introgen Therapeutics, Inc. | Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten |
| US6406745B1 (en) * | 1999-06-07 | 2002-06-18 | Nanosphere, Inc. | Methods for coating particles and particles produced thereby |
| MXPA02000053A (es) * | 1999-07-05 | 2003-07-21 | Idea Ag | Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables. |
| US20010044431A1 (en) * | 2000-03-21 | 2001-11-22 | Rodriguez Gustavo C. | Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium |
| US7029694B2 (en) * | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| AU2001253782B2 (en) * | 2000-04-26 | 2006-06-29 | Allergan Sales, Llc | Minimizing adverse experience associated with oxybutynin therapy |
| US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
| US10293056B1 (en) | 2000-05-24 | 2019-05-21 | Board Of Regents, The University Of Texas System | Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases |
| US20040092494A9 (en) * | 2000-08-30 | 2004-05-13 | Dudley Robert E. | Method of increasing testosterone and related steroid concentrations in women |
| US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| US20040241240A1 (en) * | 2001-08-10 | 2004-12-02 | Takaaki Terahara | Percutaneous absorption preparations |
| KR20030041596A (ko) * | 2001-11-20 | 2003-05-27 | 삼일페인트공업 주식회사 | 의료용 팻치에 적용되는 아크릴 점착제의 제조방법 |
| US7921999B1 (en) | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
| US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
| GB0409498D0 (en) * | 2004-04-28 | 2004-06-02 | Hunter Fleming Ltd | Transdermal steroid formulation |
| JP2008519784A (ja) * | 2004-11-12 | 2008-06-12 | イデア アクチェンゲゼルシャフト | 皮膚状態の治療における拡張表面凝集体 |
| US7833979B2 (en) * | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| US10137135B2 (en) * | 2005-08-15 | 2018-11-27 | Allergan Sales, Llc | Formulations and methods for providing progestin-only contraception while minimizing adverse side effects associated therewith |
| RS52671B (en) | 2005-10-12 | 2013-06-28 | Unimed Pharmaceuticals Llc | IMPROVED TESTOSTERON GEL AND USE PROCEDURE |
| JP2009516718A (ja) * | 2005-11-23 | 2009-04-23 | ウニベルジテート チューリッヒ | 経皮アレルゲン投与によるアレルギー治療 |
| CN101442987A (zh) * | 2005-12-14 | 2009-05-27 | 扎尔斯制药公司 | 喷雾制剂和皮肤给药方法 |
| WO2007092944A2 (en) * | 2006-02-08 | 2007-08-16 | Introgen Therapeutics, Inc. | Compositions and methods involving gene therapy and proteasome modulation |
| US8097419B2 (en) | 2006-09-12 | 2012-01-17 | Longhorn Vaccines & Diagnostics Llc | Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009 |
| US9598462B2 (en) | 2012-01-26 | 2017-03-21 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| US9481912B2 (en) | 2006-09-12 | 2016-11-01 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and identifying nucleic acid sequences in biological samples |
| US8080645B2 (en) | 2007-10-01 | 2011-12-20 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection/transport compositions and methods |
| US7825093B2 (en) | 2006-10-25 | 2010-11-02 | Amgen Inc. | Methods of using OSK1 peptide analogs |
| US20080299182A1 (en) * | 2007-03-01 | 2008-12-04 | Shuyuan Zhang | Methods and formulations for topical gene therapy |
| DK2191001T3 (en) | 2007-04-09 | 2016-09-19 | Univ Florida | RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF |
| CA2687141C (en) | 2007-05-22 | 2014-04-01 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
| US11041215B2 (en) | 2007-08-24 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | PCR ready compositions and methods for detecting and identifying nucleic acid sequences |
| US9683256B2 (en) | 2007-10-01 | 2017-06-20 | Longhorn Vaccines And Diagnostics, Llc | Biological specimen collection and transport system |
| US10004799B2 (en) | 2007-08-27 | 2018-06-26 | Longhorn Vaccines And Diagnostics, Llc | Composite antigenic sequences and vaccines |
| US8821885B2 (en) | 2007-08-27 | 2014-09-02 | Longhorn Vaccines & Diagnostics, Llc | Immunogenic compositions and methods |
| WO2009085355A2 (en) | 2007-10-01 | 2009-07-09 | Longhorn Vaccines & Diagnostics Llc | Biological specimen collection and transport system and methods of use |
| US11041216B2 (en) | 2007-10-01 | 2021-06-22 | Longhorn Vaccines And Diagnostics, Llc | Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples |
| WO2010135714A2 (en) | 2009-05-22 | 2010-11-25 | The Methodist Hospital Research Institute | Methods for modulating adipocyte expression using microrna compositions |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| EP3444346B1 (de) | 2010-04-23 | 2022-07-27 | University of Massachusetts | Aav-basierte behandlung von cholesterinerkrankungen |
| DK2561073T3 (en) | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| RS58434B1 (sr) | 2010-04-23 | 2019-04-30 | Univ Florida | Sastavi raav-guanilatne ciklaze i postupci tretiranja leberove urođene amauroze-1 (lca1) |
| KR20140145947A (ko) | 2011-03-16 | 2014-12-24 | 암젠 인크 | Nav1.3과 nav1.7의 유효한 선별적 저해제 |
| WO2012145624A2 (en) | 2011-04-21 | 2012-10-26 | University Of Massachusetts | Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies |
| US10149834B2 (en) | 2011-12-01 | 2018-12-11 | Teikoku Seiyaku Co., Ltd. | Ropinirole-containing adhesive patch |
| JP6104173B2 (ja) | 2011-12-01 | 2017-03-29 | 帝國製薬株式会社 | ロピニロール含有貼付剤 |
| EP2970408B1 (de) | 2013-03-12 | 2018-01-10 | Amgen Inc. | Hochwirksame und selektive inhibitoren von nav1.7 |
| WO2015143078A1 (en) | 2014-03-18 | 2015-09-24 | University Of Massachusetts | Raav-based compositions and methods for treating amyotrophic lateral sclerosis |
| WO2015164786A1 (en) | 2014-04-25 | 2015-10-29 | University Of Massachusetts | Recombinant aav vectors useful for reducing immunity against transgene products |
| EP3200830B1 (de) | 2014-10-03 | 2020-09-09 | University of Massachusetts | Hocheffiziente bibliotheksidentifizierte aav-vektoren |
| CA2964272A1 (en) | 2014-10-21 | 2016-04-28 | Guangping Gao | Recombinant aav variants and uses thereof |
| EP3233131A1 (de) | 2014-12-16 | 2017-10-25 | Board of Regents of the University of Nebraska | Gentherapie für juvenile neuronale ceroid-lipofuszinose |
| WO2016183292A1 (en) | 2015-05-14 | 2016-11-17 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
| SG11201804648RA (en) | 2015-12-04 | 2018-06-28 | Univ Texas | Slc45a2 peptides for immunotherapy |
| ES2898337T3 (es) | 2016-03-03 | 2022-03-07 | Univ Massachusetts | ADN dúplex lineal de extremos cerrados para la transferencia de genes no víricos |
| JP2019530737A (ja) | 2016-08-23 | 2019-10-24 | アコーオス インコーポレイテッド | ヒト対象において非加齢性聴力障害を治療するための組成物および方法 |
| US10457940B2 (en) | 2016-09-22 | 2019-10-29 | University Of Massachusetts | AAV treatment of Huntington's disease |
| EP3526333A4 (de) | 2016-10-13 | 2020-07-29 | University of Massachusetts | Aav-capsid-designs |
| US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| WO2019183605A1 (en) | 2018-03-23 | 2019-09-26 | University Of Massachusetts | Gene therapeutics for treating bone disorders |
| WO2019210269A1 (en) | 2018-04-27 | 2019-10-31 | University Of Massachusetts | Aav capsids identified by in vivo library selection |
| WO2020112967A1 (en) | 2018-11-29 | 2020-06-04 | University Of Massachusetts | Modulation of sptlc1 via recombinant adeno-associated vectors |
| EP3927380A1 (de) | 2019-02-22 | 2021-12-29 | University of Massachusetts | Oxr1-gentherapie |
| US20220340643A1 (en) | 2019-09-13 | 2022-10-27 | Rutgers, The State University Of New Jersey | Aav-compatible laminin-linker polymerization proteins |
| BR112022016596A2 (pt) | 2020-02-21 | 2022-11-16 | Akouos Inc | Composições e métodos para o tratamento de debilitação auditiva não associada à idade em um indivíduo humano |
| WO2021202494A1 (en) | 2020-03-31 | 2021-10-07 | University Of Massachusetts | Aav capsids variants and uses thereof |
| CA3178726A1 (en) | 2020-05-21 | 2021-11-25 | Gregory LIZEE | T cell receptors with vgll1 specificity and uses thereof |
| CN116406305A (zh) | 2020-08-17 | 2023-07-07 | 麻省理工学院 | Shank3基因治疗方法 |
| KR20230117177A (ko) | 2020-12-03 | 2023-08-07 | 유니버시티 오브 매사추세츠 | 진행성 골화성 섬유이형성증을 위한 신규 유전자 치료제의개발 |
| KR20240017813A (ko) | 2021-05-10 | 2024-02-08 | 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. | 신경질환 치료용 약학적 조성물 |
| IL311572A (en) | 2021-09-30 | 2024-05-01 | Akouos Inc | Compositions and methods for treating KCNQ4-related hearing loss |
| WO2023164545A1 (en) | 2022-02-23 | 2023-08-31 | Massachusetts Institute Of Technology | Methods for upregulating shank3 expression |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4954487A (en) * | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
| IL61721A (en) * | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
| US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
| JPS60123417A (ja) * | 1983-12-07 | 1985-07-02 | Nitto Electric Ind Co Ltd | 薬物投与部材 |
| JPS6160620A (ja) * | 1984-09-03 | 1986-03-28 | Teijin Ltd | ピログルタミン酸エステル類を含有する医薬品組成物 |
| US5296230A (en) * | 1985-02-25 | 1994-03-22 | Rutgers, The State University Of New Jersey | Transdermal fertility control system and process |
| US4762851A (en) * | 1985-11-29 | 1988-08-09 | Merck & Co., Inc. | Pyroglutamic acid esters used as dermal penetration enhancers for drugs |
| US5023084A (en) * | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
| US4994267A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Transdermal acrylic multipolymer drug delivery system |
| GB8811408D0 (en) * | 1988-05-13 | 1988-06-15 | Unilever Plc | Cosmetic composition |
| US5200190A (en) * | 1988-10-11 | 1993-04-06 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneous pharmaceutical preparation |
| US5512292A (en) * | 1990-10-29 | 1996-04-30 | Alza Corporation | Transdermal contraceptive formulations methods and devices |
| JPH04342532A (ja) * | 1991-05-21 | 1992-11-30 | Sekisui Chem Co Ltd | 経皮吸収貼付剤 |
| JP3086288B2 (ja) * | 1991-07-23 | 2000-09-11 | 扶桑薬品工業株式会社 | 経皮吸収製剤 |
| JP2948423B2 (ja) * | 1992-08-19 | 1999-09-13 | 富士写真フイルム株式会社 | カリウムイオン分析用イオン選択電極 |
| US5460820B1 (en) * | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
| AU692504B2 (en) * | 1993-12-27 | 1998-06-11 | Akzo Nobel N.V. | Percutaneously absorbable preparation |
| FR2717688B1 (fr) * | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
| JPH0827003A (ja) * | 1994-07-22 | 1996-01-30 | Sekisui Chem Co Ltd | 経皮吸収製剤 |
| US5780050A (en) * | 1995-07-20 | 1998-07-14 | Theratech, Inc. | Drug delivery compositions for improved stability of steroids |
| DE19629468A1 (de) * | 1996-07-11 | 1998-01-15 | Schering Ag | Transdermale therapeutische Systeme |
-
1996
- 1996-07-19 US US08/683,892 patent/US5783208A/en not_active Expired - Lifetime
-
1997
- 1997-07-02 HU HU9904369A patent/HUP9904369A3/hu unknown
- 1997-07-02 CN CNB2004100831783A patent/CN100536835C/zh not_active Expired - Fee Related
- 1997-07-02 CA CA002259532A patent/CA2259532C/en not_active Expired - Lifetime
- 1997-07-02 EP EP97933279A patent/EP0921774B1/de not_active Expired - Lifetime
- 1997-07-02 JP JP50695598A patent/JP4212115B2/ja not_active Expired - Lifetime
- 1997-07-02 CN CNB971965633A patent/CN1204859C/zh not_active Expired - Fee Related
- 1997-07-02 DK DK97933279T patent/DK0921774T3/da active
- 1997-07-02 AU AU36503/97A patent/AU714590B2/en not_active Ceased
- 1997-07-02 PT PT97933279T patent/PT921774E/pt unknown
- 1997-07-02 IL IL12770897A patent/IL127708A/en not_active IP Right Cessation
- 1997-07-02 KR KR1019997000406A patent/KR100628796B1/ko not_active IP Right Cessation
- 1997-07-02 PL PL33123997A patent/PL188009B1/pl not_active IP Right Cessation
- 1997-07-02 BR BR9710738A patent/BR9710738A/pt not_active Application Discontinuation
- 1997-07-02 ES ES97933279T patent/ES2271970T3/es not_active Expired - Lifetime
- 1997-07-02 DE DE69736671T patent/DE69736671T2/de not_active Expired - Lifetime
- 1997-07-02 WO PCT/US1997/011673 patent/WO1998003137A1/en active IP Right Grant
- 1997-07-02 AT AT97933279T patent/ATE339172T1/de not_active IP Right Cessation
- 1997-07-02 NZ NZ333558A patent/NZ333558A/xx unknown
- 1997-07-07 ZA ZA9706035A patent/ZA976035B/xx unknown
-
1999
- 1999-01-15 NO NO19990179A patent/NO325232B1/no not_active IP Right Cessation
-
2000
- 2000-01-03 HK HK00100001A patent/HK1020864A1/xx not_active IP Right Cessation
-
2005
- 2005-11-18 HK HK05110412.4A patent/HK1078470A1/xx not_active IP Right Cessation
-
2006
- 2006-09-26 JP JP2006261578A patent/JP2006342186A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO325232B1 (no) | Transdermalt plaster for administrering av estradiol og et annet steroid | |
| AU710760B2 (en) | Drug delivery compositions for improved stability of steroids | |
| US5693335A (en) | Skin permeation enhancer composition for use with sex steroids | |
| DK171138B1 (da) | Transdermal absorptionsdosisenhed til behandling af postmenopausesyndrom | |
| RU2154455C2 (ru) | Чрескожные терапевтические системы, содержащие половые стероиды | |
| JP3273430B2 (ja) | エストロゲン含有ゲル製剤 | |
| NO180567B (no) | Befruktningshindrende og/eller syklusregulerende middel for transdermal applikasjon | |
| JPH07330609A (ja) | エストロゲンおよび／またはプロゲストゲンを投与するのに用いるスチレン−イソプレン−スチレン共重合体ベースの経皮マトリックスシステム | |
| CA2227538A1 (en) | Hormone patch | |
| RU2317813C2 (ru) | Содержащие стероидный гормон трансдермальные терапевтические системы, включающие монокаприлат пропиленгликоля | |
| WO2011000210A1 (zh) | 促渗剂组合物及其透皮给药系统中的应用 | |
| CA2614187A1 (en) | Drospirenone containing transdermal drug delivery devices and methods of delivery thereof | |
| AU681383B2 (en) | Active-substance patch for releasing estradiol to the skin | |
| JP3043071B2 (ja) | エストロゲンを含む経皮的投与装置 | |
| WO1997040792A1 (en) | Transdermal administration of steroid hormones using diethanolamides of c12-c18 fatty acids as permeation enhancers | |
| MXPA99000683A (en) | Matrix for the transdermal release of a pharmacy, to coordinate estradiol and another estero | |
| JPH04342531A (ja) | 経皮吸収製剤 | |
| JPH07101853A (ja) | 経皮吸収貼付剤 | |
| JP2004075538A (ja) | ノルエチステロン含有外用貼付剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |